STI ppt.ppt

Senior Lecturer à Haramaya University
26 May 2022
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
STI ppt.ppt
1 sur 41

Contenu connexe

Similaire à STI ppt.ppt

MANAGEMENT OF LOWER ABDOMINAL PAIN IN FEMALES AND GENITAL ULCERSMANAGEMENT OF LOWER ABDOMINAL PAIN IN FEMALES AND GENITAL ULCERS
MANAGEMENT OF LOWER ABDOMINAL PAIN IN FEMALES AND GENITAL ULCERSShiksha Choytoo
Pelvic inflammatory diseasePelvic inflammatory disease
Pelvic inflammatory diseasedrmcbansal
Pelvic  Inflammatory  Disease (PID)Pelvic  Inflammatory  Disease (PID)
Pelvic Inflammatory Disease (PID)Walid Ahmed
Syndromic management of sti'sSyndromic management of sti's
Syndromic management of sti'sNayeem Baig
who guidlines for Hivwho guidlines for Hiv
who guidlines for HivShoaib Magsi
Sexually transmitted diseasesSexually transmitted diseases
Sexually transmitted diseasesNamita Batra

Plus de Haramaya University

DRUG INFORMATION CENTER.pdfDRUG INFORMATION CENTER.pdf
DRUG INFORMATION CENTER.pdfHaramaya University
PHARMACEUTICAL ANALYSIS-II.pptPHARMACEUTICAL ANALYSIS-II.ppt
PHARMACEUTICAL ANALYSIS-II.pptHaramaya University
LITERATURE EVALUATION.pdfLITERATURE EVALUATION.pdf
LITERATURE EVALUATION.pdfHaramaya University
LITERATURE EVALUATION.pptxLITERATURE EVALUATION.pptx
LITERATURE EVALUATION.pptxHaramaya University
PHARMACOLOGY I.pptxPHARMACOLOGY I.pptx
PHARMACOLOGY I.pptxHaramaya University
PHARMACOLOGY I.pptxPHARMACOLOGY I.pptx
PHARMACOLOGY I.pptxHaramaya University

Dernier

Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and ...Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and ...
Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and ...PeerVoice
NCS routineNCS routine
NCS routineBenjamin614958
flowzz.com Marketupdate Teaserflowzz.com Marketupdate Teaser
flowzz.com Marketupdate TeaserDavidRonen3
Chương 6. Tài liệu EU GMP.pdfChương 6. Tài liệu EU GMP.pdf
Chương 6. Tài liệu EU GMP.pdfCông ty cổ phần GMPc Việt Nam | Tư vấn GMP, HS GMP, CGMP ASEAN, EU GMP, WHO GMP
AdulterationAdulteration
AdulterationSalveShruti1
COPD [Autosaved].pptxCOPD [Autosaved].pptx
COPD [Autosaved].pptxmokshadatalele

STI ppt.ppt

Notes de l'éditeur

  1. Notes: Unit 13 should take approximately 1 hour to complete: Step 1: Unit Introduction and Learning Objectives (Slides 1-2) – 5 minutes Step 2: STDs and STIs Overview; Interaction between HIV and STIs (Slides 3-8) – 10 minutes Step 3: Syndrome Approach; STI Syndromes (Slides 9-39) – 40 minutes Step 4: Discussion of Key Points (Slides 40-41) – 5 minutes
  2. Notes: Step 1: Unit Introduction and Learning Objectives (Slides 1-2) – 5 minutes
  3. Notes: Step 2: STDs and STIs Overview; Interaction between HIV and STIs (Slides 3-8) – 10 minutes Some people use the terms STI and STD interchangeably but they actually have different meaning.
  4. Notes: Social and economic consequences of STIs: Husband abandoning infertile wives Beatings and/or divorce Financial burden of treating STIs and their complications Antibiotic resistance making low cost regimens ineffective
  5. Notes: Mechanism: Mucosal and skin barrier disruption Inflammation increasing CD4 cell concentration in genital areas Infection leading to increased HIV expression in genital secretions
  6. Note: Bacterial vaginosis and candidiasis are also common causes of reproductive tract infections (vaginal discharge), but are not sexually transmitted (currently debatable).
  7. Notes: Step 3: Syndromic Approach STI Syndromes (Slides 9-39) – 40 minutes “Syndromic Management” contrasts with “Etiologic Management.” Whereas etiologic management focuses on identifying and treating a specific etiology causing clinical symptoms, syndromic management considers the likely causative agent(s) for a given clinical syndrome and treats accordingly, without regard for identifying the specific infection. Benefits of etiologic management: focused, specific therapy, avoiding the cost and toxicity of unnecessary medications. Benefits of syndromic management: laboratory testing not needed; treatment provided immediately, without need for lab results; effective in resource-limited settings.
  8. Notes: (Source: National Guideline for the Management of STIs, March 2005) The gonococcal isolates in the validation study conducted by EHNRI/MOH in Ethiopia were uniformly sensitive to ciprofloxacin making it the drug of choice. However it can not be given for pregnant women and children, in which case Spectinomycin can be used.
  9. Notes: Recurrent discharge may reflect poor adherence to initial treatment regimen, e.g., due to GI upset. Recurrent discharge may also reflect re-infection. If neither of these seem to be present, treat for T. vaginalis. T. vaginalis was found to be common (second among causes of urethral discharge) among Ethiopian men with urethral discharge syndrome as seen in the validation study conducted by EHNRI/MOH. Treatment – Metronidazole 2g po, stat. Source: Validation of STI Treatment Algorithms, 2003-2004, EHNRI/MOH
  10. Note: The first three are sexually acquired and the last two are endogenous infections
  11. Note: Risk factors include age <25, trading sex, multiple or new partners in the last three months Source: National Guideline for the Management of Sexually Transmitted Infections, March 2005
  12. Notes: If assessment of risk for STI is positive likely etiologies include Neisseria, Chlamydia and Trichomonas and hence Ciprofloxacin or spectinomycin, doxycycline and metronidazole are drugs of choice respectively. If assessment of risk of STI is negative, likely etiologies are Gardnerella and candida; the drugs of choice being Metronidazole and clotrimazole
  13. Notes: According to the validation study conducted by MOH/ EHNRI in Ethiopia, it was found out that in genital ulcer diseases, one or more pathogens were found in males and females in 76% and 82.45 of the cases respectively. HSV2 alone was the leading cause of GUD in both males and females, constituting 44% and 75.5% of cases respectively. But the prevalence of HSV2 as it occurs in combination with other pathogens or alone constituted 52% and 78.45% in males and females respectively. Altogether, HSV2 was responsible for 70% of all GUD causes. Syphilis was the second leading cause in males (28%) as compared with females (6%). Chanchroid constituted for only 4% of GUD cases. ( Source: Validation study of the syndromic algorithm approach of the management of STIs in Ethiopia , August 2004) Source of above recommendations: National Guideline for the Management of STIs , March 2005, Ethiopia
  14. Note: In about 75% of EM, HSV is the precipitating event. Patients with severe HSV-associated Em should be on chronic oral suppressive Tx
  15. Notes: Persistence for >1 month is an AIDS-defining condition. Chronic herpes simplex can be painful and debilitating involving not only the genital area but the mouth, lips, esophagus and skin. Treatment is available for suppression but can be very expensive and will need to be taken for a long time. These can last months and may be improved with ARV treatment. Herpetic lesions can also become secondarily infected leading to more morbidity in the HIV infected patient.
  16. Note: Herpes genitalis outbreak on the penile shaft due to HSV-2.
  17. Note: Source: 2004 medical management of HIV. John G Bartlett & Joel E. Gallant Acyclovir, Famciclovir, and Valacyclovir are category B. Acyclovir is not teratogenic, but has potential to cause chromosomal damage at high doses. The CDC recommends use of acyclovir during pregnancy for severe HSV outbreaks and varicella. Use for prophylaxis in pregnancy is being investigated.
  18. Notes: Ask participants to identify what organisms are being treated with each antibiotic: Ciprofloxacin, Spectinomycin, Ceftriaxone: Gonorrhea Doxycycline: Chlamydia Metronidazole, Chloramphenicol: Anaerobic (and other) bacteria antibiotics have broader spectrum of action than just the organisms identified above, but this exercise helps reinforce what organisms cause PID, and the connection between causative agents and specific treatments.
  19. Note: Ciprofloxacin is indicated in Ethiopia for treatment of Gonorrhea
  20. Notes: Some experts advise treating inguinal bubo for three weeks (Source national guideline for the management of STIs, March 2005)
  21. Notes: Spectinomycin 50 mg /kg im stat can be replaced for ceftriaxone for gonococcal ophtalmia in Ethiopian setting. In the case of herpes conjunctivitis Acyclovir 5-10 mg /kg iv daily for 10 days is indicated Source: National Guideline for the management of STIs, March 2005
  22. Note: Step 4: Discussion of Key Points (Slides 40-41) – 5 minutes